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Introduction 
The immune system & autoantibodies 
The immune system is defined as the biological system of protecting the host from 
infection and the damage they cause. It consists of two different mechanisms, the 
innate immune system and adaptive immune system. The innate immune system 
is the first line defense system by macrophages, natural killer cells, dendritic cells, 
granulocytes, and etc. The innate immune response is fast and non-specific, 
whereas the adaptive immune response is usually slow to develop and highly 
specific to the antigens. In addition, the adaptive immune system can also form 
memory resulting in fast response after subsequent presentation of the same 
antigens. The adaptive immune system is mainly composed of the B and T 
lymphocytes, which are derived from the bone marrow. B cells become mature in 
the bone marrow; however, the precursors of T cells migrate to the thymus where 
they develop as mature T cells. Upon activation, B cells can differentiate into the 
plasma cells which secrete antibodies against antigens. T cells can recognize the 
signal from antigen presenting cells, then differentiate either into helper T cells 
(CD4+) that activate other cells of the immune system or cytotoxic T cells (CD8+) 
that directly destroy the infected cells (Murphy, 2012).  
Although the fundamental role of the immune system is to distinguish non-self 
from self-molecules, sometimes it produces antibodies that react to self-
molecules which are defined as autoantibodies. In healthy individuals, the high 
affinity of self-reactive T and B lymphocytes in the thymus and bone marrow are 
eliminated (negative selection) or functionally inactivated (anergy) to maintain 
self-tolerance. The most common autoantibodies in healthy individuals are 
mainly low affinity IgM, and occasionally low titer of IgG (Elkon et al., 2008).  
Normally, these autoantibodies do not cause serious harm to the host. Study has 
shown their beneficial effects, such as the autoantibodies against TNF-α have 
been reported to suppress rheumatoid arthritis (Wildbaum et al., 2003). The self-
reactive lymphocytes are required for a functional immune system. However, the 
strong response to self-antigens can lead to autoimmune diseases that are 
characterized by tissue damage. For example, in rheumatoid arthritis, 
autoreactive T cells against antigens of joint synovium can result in joint 
inflammation and arthritis (Lee, D. M. et al., 2001). In systemic lupus 
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erythematosus (SLE), there are autoantibodies produced against DNA, 
chromatin proteins, and ubiquitous ribonucleoprotein antigens which lead to 
glomerulonephritis, vasculitis, and rash (Rahman et al., 2008). In multiple 
sclerosis, it was shown that autoreactive T cells against myelin antigens produce 
the sclerotic plaques in the brain with destruction of myelin sheaths (Correale et 
al., 2017). Type 1 diabetes is an autoimmune disease characterized by 
autoreactive T cells against pancreatic islet cell antigens, which can cause 
destruction of  pancreatic islet β cells resulting in non-production of insulin (Li 
et al., 2017).  
There are multiple tolerance mechanisms that can prevent autoimmunity, and 
these mechanisms are named as checkpoints. Each checkpoint prevents 
autoreactive responses, and together they can provide efficient protection against 
autoimmunity. The central tolerance mechanism eliminates those newly formed 
strongly autoreactive lymphocytes in the thymus and bone marrow (Hogquist et 
al., 2005; Nemazee, 2017). In the periphery, regulatory T cells (Tregs) suppress 
the T cell response through cytokine secretion and intercellular signals and self-
reactive B and T cells can also be eliminated. The self-reactive lymphocytes 
remain in low affinity and can be ignored, but they can also be activated under 
certain circumstances (Cyster et al., 1994; Goodnow et al., 1989; Goodnow et al., 
2005; Nemazee, 2006; Russell et al., 1991; Shlomchik, 2008). 
The mechanisms of autoimmune disease have not been elucidated yet. An 
explanation is that it’s a combination of genetic susceptibility, self-tolerance 
breakdown, and environmental triggers such as infections. In human, AIRE gene 
can cause APS-1 (autoimmune polyglandular syndrome 1). CTLA4 gene is 
associated with Grave’s disease, type 1 diabetes, and etc. (Rioux et al., 2005). The 
circulating lymphocytes normally have a low affinity for self-antigens, however, 
they are activated when their autoantigens are also the ligands for Toll-like 
receptors (TLRs). TLRs are an important protein family expressed on 
macrophages and other immune cells, which can recognize and bind to different 
antigens. For example, Toll-like receptor 9 (TCR9) binds to unmethylated CpG 
sequences in the DNA which is common in bacteria and apoptotic mammalian 
cells. Once the unmethylated CpG sequences are released as apoptotic fragments, 
they are recognized and bound by B cell receptors that are specific for chromatin 
components, the complex can be internalized into B cells. These sequences bind 
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to TLR9 (expressed in the cytoplasm of B cells) intracellularly, leading to a co-
stimulatory signal, together with the signal from B cell receptor, activating the 
anti-chromatin B cells (Marshak-Rothstein, 2006). Besides, a theory of molecular 
mimicry proposed that when pathogens share similar structure with human 
proteins, it will result in the immune system targeting on self-proteins, which will 
also lead to autoimmune response (Plotz, 2003; Rose, 2001).  
Autoimmunity in the brain 
The brain is an immunologically privileged site. It is surrounded by the blood-
brain barrier (BBB) that prevents the entry of microorganisms and lymphocytes, 
to protect the neuronal tissue from infection. At the same time, the BBB also 
blocks complete clearance of pathogens that entered the brain, or protects tumors 
in the brain (Joyce et al., 2015; Miller et al., 2016).  The BBB is composed of brain 
microvascular endothelial cells, astrocytes and pericytes. The brain 
microvascular endothelial cells form tight junctions that prevent large molecules 
to enter. Astrocytes and pericytes help the microvascular endothelial cells to 
maintain the intact barrier property, which is shown in figure 2 (Kim, K. S., 2008).  
Figure 1   The structure of the blood-brain barrier. The brain microvascular endothelial 
cells form tight junctions that prevent large molecules to enter the brain. Astrocytes and pericytes 
help the microvascular endothelial cells to maintain the intact barrier property, modified from 
(Kim, K. S., 2008). 
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Autoimmune encephalitis refers to an inflammation in the brain, associated with 
antibodies against neuronal and synaptic proteins. Once the BBB breaks down, 
activated T cells enter the brain, which results in further progression of the brain 
inflammation. For example, in multiple sclerosis, brain inflammation leads to the 
permeability of the BBB, and activated T cells that are specific for central nervous 
system (CNS) antigen reencounter the antigen presented by microglia. Th17 and 
Th1 cells infiltrate into the brain and produce IL-17 and IFN-γ, which recruit and 
activate myeloid cells that exacerbate the inflammation, resulting in further 
recruitment of T cells, B cells and innate immune cells. Autoreactive B cells 
produce autoantibodies against myelin, ultimately leading to demyelination and 
an alteration of neuronal function (Steinman, 1996).  
There are different ways for the antibodies and immune cells to cross the BBB: 
(I) Systemic cytokines break down the tight junctions in the brain-cerebrospinal 
fluid barrier, allowing the antibodies or immune cells to enter. (II) Olfactory 
ensheathing glia facilitate transport of IgGs or immune cells into the brain. (III) 
Inflammatory cytokines in the blood damage the tight junctions of BBB, allowing 
the entry of antibodies or immune cells. (IV) Fc receptor mediates transcytosis 
from the blood vessels, e.g. in systemic lupus erythematosus (Knowland et al., 
2014; Platt et al., 2017; Zhao et al., 2015).  
Anti-NMDA receptor encephalitis 
Dalmau and colleagues described a new autoimmune disease termed as ‘anti-
NMDA receptor encephalitis’ in 2007 (Dalmau et al., 2007). The authors reported 
that those patients had paraneoplastic encephalitis accompanied by the presence 
of anti-NMDA receptor antibodies in the serum/cerebrospinal fluid. They also 
described that this disease is associated with ovarian teratoma, and the patients 
were mostly young females. Furthermore, these patients developed psychiatric 
symptoms such as psychosis, seizures, memory deficits, and etc. The mechanism 
of anti-NMDA receptor encephalitis was interpreted as a decreased density of 
surface NMDA receptors due to binding of the autoantibodies against NMDA 
receptors in postsynaptic dendrites (Dalmau et al., 2008; Dalmau et al., 2018; 
Dalmau et al., 2011; Dalmau et al., 2007).  
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NMDA receptor & brain function 
The NMDA receptors belong to the ionotropic glutamate receptor family.  
Glutamate is the most important neurotransmitter in normal brain function, 
especially in the excitatory neurons in the CNS. The glutamate is synthesized in 
the presynaptic terminals and packaged into synaptic vesicles, released into the 
synaptic cleft, and bound to the glutamatergic receptors of postsynaptic neurons 
(Halterman, 2005; Niciu et al., 2012). There are two types of glutamate receptors 
on the post synaptic neurons: the metabotropic glutamate receptors (mGluRs) 
and the ionotropic glutamate receptors (iGluRs). The mGluRs are G-protein-
coupled receptors, with eight different subtypes (mGluR1-8), and these receptors 
modulate postsynaptic ion channels indirectly by coupling to different 
pharmacological agents (Crupi et al., 2019). There are three major iGluRs 
identified: NMDA receptors (NMDAR), AMPA receptors, and kainate receptors. 
The iGluRs are nonselective cation channels, allowing Na+, and K+ to pass, thus 
produce excitatory postsynaptic responses. As shown in Figure 2A, the NMDA 
receptor is a transmembrane protein. When the membrane is at resting potential, 
the NMDA receptor is blocked by Mg2+ ion in the channel pore (Figure 2B). Mg2+ 
is pushed out of the channel pore during depolarization of the postsynaptic 
neuronal membrane, which allows other cations (Ca2+ in addition to Na+ and K+) 
influx, resulting in the activation of the NMDA receptor (Figure 2C). The binding 







Figure 2   The mechanism of NMDA receptor activation. (A) The structure of NMDA 
receptor channel as transmembrane protein and its binding sites of Mg2+, glutamate and glycine. 
Through the receptor pore, Ca2+, Na+ and K+ can pass through. (B) Synapse at the resting 
potential; Mg2+ blocks NMDA receptor preventing cation flux through receptor. (C) The NMDA 
receptor at depolarization state: During depolarization, Mg2+ is removed from the channel pore, 
which allows other cations (Ca2+ in addition to Na+ and K+) influx, resulting in the activation of 
the NMDA receptor (Halterman, 2005). 
There are 7 subunits of NMDA receptor identified so far: GluN1 subunits, 4 
GluN2 subunits (GluN2A-GluN2D), and 2 GluN3 subunits (GluN3A, GluN3B). 
All of these subunits are encoded by separate genes which translated into 900 to 
over 1480 amino acids (Paoletti et al., 2013). The NMDA receptor is a 
heterotetrametric complex, GluN1 subunit is the obligatory subunit in all 
functional NMDA receptors (Kew et al., 2005). It was shown that the subunits of 
NMDA receptor are expressed differentially in developing and adult brains, also 
among different brain regions (Akazawa et al., 1994; Henson et al., 2010; Monyer 
et al., 1994). 
NMDA receptors are critical for the foundation of learning and memory through 
mechanism of long-term potentiation (LTP) (Lynch et al., 1983; Nicoll, 2017). 
Moreover, dysfunction of NMDA receptor is found in many brain disorders, such 
as in Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, anti-
NMDAR encephalitis, and etc. (Paoletti et al., 2013).  
NMDAR autoantibodies in human health and disease 
Dalmau and his colleagues claimed that anti-NMDA receptor encephalitis was 
caused by the IgG class of the anti-NMDA receptor antibodies (Dalmau et al., 
2008; Dalmau et al., 2007).  
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Meanwhile, this view has been challenged by the work form our group. We 
reported a similar seroprevalence of autoantibodies against NMDA receptor 
subunit GluN1 (NMDAR1-AB) in both healthy and disease human groups, and 
an increase upon aging. Moreover, all these antibodies are functional regardless 
of the immunoglobulin classes (IgA, IgG, and IgM), and they also do not differ 
regarding epitope binding to the NMDA receptors (Castillo-Gomez et al., 2017; 
Dahm et al., 2014; Ehrenreich, 2017, 2018; Hammer et al., 2014).   
Investigation of NMDAR1-AB in non-human mammals (Project 1) 
In 2015, the NMDAR1-AB were first described in non-human mammals, a polar 
bear named Knut, in Berlin Zoological Garden. After epileptic seizures in 2011, 
the pathological analyses in Kunt’s brain showed signs of encephalitis, and 
NMDAR1-AB were found in his cerebrospinal fluid (Prüss et al., 2015). We 
believe that the NMDAR1-AB belong to the natural autoantibody repertoire, thus 
they might also be found in other non-human mammals. To prove it, we screened 
the NMDAR1-AB seroprevalence in mice, rats, dogs, cats and monkeys (baboons 
and rhesus macaques). 
In addition, we immunized both ApoE-/- (with compromised BBB) and WT mice 
with a mixture of 4 peptides against GluN1 subunit of the NMDA receptor. After 
4 weeks of immunization, we performed open field testing with MK801 (NMDA 
receptor antagonist) treatment and looked for inflammation markers in the brain 
after the termination of the experiment. All the results are presented and 
discussed in Chapter 2 (Project 1). 
Investigation of potential NMDAR1-AB inducers (Project 2) 
Shown in the cases of anti-NMDAR encephalitis, the presence of NMDAR1-AB 
seems to be associated with tumor, such as ovarian teratoma (Dalmau et al., 
2008; Dalmau et al., 2011; Dalmau et al., 2007). Other studies have also 
suggested the association of NMDAR1-AB with patients who were infected with 
influenza A/B (Castillo-Gomez E, 2016; Hammer et al., 2014). Herpes simplex 
virus encephalitis was also reported as a trigger for NMDAR1-AB production 
(Prüss et al., 2012).  
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In our design, we investigated more potential inducers including brain injury, 
checkpoint inhibitor, and chronic life stress in mice/human, which is detailed 
described in Chapter 3 (Project 2). 
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Scope of the present work 
As discussed in the introduction, it remains unclear what is the mechanism 
behind the anti-NMDA receptor encephalitis. What are the effects of carrying 
high level of NMDAR1-AB and what are the inducers of the NMDAR1-AB 
formation? Thus, my present thesis aimed to answer these questions.  
In my 1st project, we aimed at (i) the seroprevalence and functionality of 
NMDAR1-AB in non-human mammals; (ii) the consequences of high circulating 
levels of endogenously produced NMDAR1-AB of the IgG class (by 
immunization) in mice with compromised BBB, by behavioral and morphological 
testing. 
In my 2nd project, we aimed at (i) the course of spontaneously formed NMDAR1-
AB in mouse and human upon long-term observation, with intact and 
compromised BBB; (ii) brain lesion (cryolesion mocel) as a potential inducer of 
NMDAR1-AB; (iii) immune checkpoint inhibitor: CTLA4-AB as a potential 
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2. Project I:  
Uncoupling the widespread occurrence of anti 
NMDAR1 autoantibodies from neuropsychiatric 
disease in a novel autoimmune model 
Overview of project I 
NMDAR1-AB (IgG class) has been reported to be associated with anti-NMDAR1 
encephalitis by Dalmau and colleagues (Dalmau et al., 2008; Dalmau et al., 2011; 
Dalmau et al., 2007). However, previous work from our group showed a 
considerable seroprevalence in health as well as in disease groups, and the 
seroprevalence increases with age (Castillo-Gomez et al., 2017; Dahm et al., 
2014; Hammer et al., 2014). The NMDAR1-AB in different groups also exhibited 
similar functionality and epitopes binding to the NMDA receptor (Castillo-Gomez 
et al., 2017; Hammer et al., 2014).  
Next, there are still several questions that we would like to address:  
(I) Whether the properties of NMDAR1-AB are unique in human or 
not? To answer this question, we screened the existence of NMDAR1-AB in the 
blood samples of dogs, cats, mice, rats, and monkeys (baboons and rhesus 
macaques). We found NMDAR1-AB in all the species tested. Furthermore, an 
age-dependent increase of NMDAR1-AB in all the species except for monkeys 
(baboons and rhesus macaques), which already had a high seroprevalence at an 
early age. Therefore, we hypothesized that chronic life stress might be associated 
with the NMDAR1-AB production. Since the monkeys were not domesticated 
animals but were the 1st or 2nd generation in captivity. Driven by this hypothesis, 
we wondered if there is a pre-disposition for high seroprevalence of NMDAR1-
AB in humans if they were also under chronic life stress. We screened the 
NMDAR1-AB in the blood samples from the 1st and 2nd generation of human 
migrants in our GRAS (Göttingen Research Association for Schizophrenia) 
database (Begemann et al., 2010; Hammer et al., 2014; Ribbe et al., 2010; 
Stepniak et al., 2015). GRAS is a unique database established in our group, with 
the design of associating the genetic information with neuropsychiatric 
phenotypes. Indeed, we observed a high seroprevalence of NMDAR1-AB in the 
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young migrants, especially IgA class. This served as an indirect indicator that 
chronic life stress could be one of the inducers of the NMDAR1-AB. 
(II) What are the effects of carrying high titer of NMDAR1-AB in mice? 
In order to study the effect of NMDAR1-AB produced endogenously in mice, we 
immunized both WT and ApoE-/- (Apolipoprotein E deficient) mice with GluN1 
antigen cocktail which contains 4 different peptides from the extracellular 
structure of NMDA receptor. Since apolipoprotein E (ApoE) mediates lipoprotein 
uptake, the ApoE-/- mice have a high cholesterol level, which is believed to 
increase the BBB permeability. The level of the BBB breakdown has shown to be 
increased upon aging or after injury in mice (Hafezi-Moghadam et al., 2007; 
Methia N et al., 2001). Another study reported that the BBB breakdown is likely 
due to the activation of cyclophilin A (CypA) which led to vascular defects in the 
ApoE-/- mice (Bell et al., 2012).  
The titer of NMDAR1-AB was confirmed by ELISA, and it showed a similar 
kinetics as ovalbumin (OVA). In the open field test, we observed a higher level of 
locomotion after MK801 (dizocilpine) treatment in ApoE-/- mice carrying 
NMDAR1-AB compared to the WT mice carrying NMDAR1-AB. MK801 is a 
noncompetitive antagonist of the NMDA receptor, binding to the core of the 
NMDA receptor channel. Studies have shown that administration of MK801 in 
rodents induce locomotor hyperactivity, it was used in modelling psychosis-like 
behavior in rodents (Hammer et al., 2014; Lee, G. et al., 2019; Vishnoi et al., 
2015; Zuo et al., 2006). Next, we wondered if encephalitis was developed due to 
a high titer of NMDAR1-AB IgG classes produced in mice. However, no signs of 
inflammation was detected in mouse brains, clearly suggesting that the mice 
carrying functional NMDAR1-AB do not necessarily develop anti-NMDA 
receptor encephalitis. Therefore, we hypothesized that pre-existing encephalitis 
plus circulating NMDAR1-AB will lead to Dalmau’s anti-NMDAR1 encephalitis. 
This project is currently running in our group by immunizing a mouse model 
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Original publication 
Pan H*, Oliveira B*, Saher G*, Dere E, Tapken D, Mitjans M, Seidel J, 
Wesolowski J, Wakhloo D, Klein-Schmidt C, Ronnenberg A, Schwabe K, Trippe 
R, Mätz-Rensing K, Berghoff S, Al-Krinawe Y, Martens H, Begemann M, Stöcker 
W, Kaup FJ, Mischke R, Boretius S, Nave KA, Krauss JK, Hollmann M, Lühder F, 
Ehrenreich H. Uncoupling the widespread occurrence of anti-NMDAR1 
autoantibodies from neuropsychiatric disease in a novel autoimmune model. Mol 
Psychiatry. 2019 Oct; 24(10):1489-1501. doi: 10.1038/s41380-017-0011-3. 
Epub 2018 Feb 9. 
* Shared first authorship. 
 
Personal contribution: I was responsible for the conduction of most of the 
experiments and data analyses of this study under the supervison of HE and FL, 
including cross-validation of NMDAR1-AB detection method (Figure 1a); 
NMDAR1-AB determination in mice, rats, dogs, cats, baboons, rhesus macaques 
(Figure 1b), and human migrants (Figure 1c migrants); mouse immunization 
study: all the blood collection, ELISA (Figure 2c), behavior tests (Figure 2d), 
immunohistochemistry staining and quantification for CD3 (Figure 2e CD3). In 
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3. Project II:  
Multiple inducers and novel roles of autoantibodies 
against the obligatory NMDAR subunit NR1: A 
translational study from chronic life stress to brain 
injury 
Overview of project II 
After we investigated the effects of NMDAR1-AB in both WT and ApoE-/- mice 
with compromised BBB (Pan et al., 2019), the next question which intrigued us 
was: what are the inducers of the NMDAR1-AB formation? 
In this project, we employed multiple approaches, e.g. brain lesion, checkpoint 
inhibitor treatment, and chronic life stress, to answer our questions.  
(I) The course of the NMDAR1-AB in mice and humans. We observed 
both in WT and ApoE-/- mice, that the NMDAR1-AB can stay positive, or stay 
negative, or being transiently positive (loss or gain of Ig classes) over a period of 
3-6 months. Similar observations were made in human patients, from 24h till 1-
3 years after ischemic stroke.  
(II) Brain lesion (cryolesion in mice) as a potential inducer. We used a 
standardized brain lesion model: cryolesion (Sirén et al., 2006)  in 4 weeks old 
male C57BL/6J mice, and detect the NMDAR1-AB seroprevalence 4 months after 
the surgery/sham. We found increased level of IgG and IgM classes of NMDAR1-
AB in the cryolesion group compared to the sham group, also a slight increase of 
AB diversity in the cryolesion group.  
(III) CTLA4 genetic predisposition in human & CTLA4-AB treatment 
in mice. In human, CTLA4 (Cytotoxic T-Lymphocyte Associated antigen 4) 
gene, is associated with autoimmune diseases, and there were studies which 
reported that the patients treated with checkpoint inhibitor: CTLA4-AB (also 
named as ipilimumab) often developed autoimmune diseases (Bartels et al., 
2019; de Moel et al., 2019; Ikegami et al., 2006; June et al., 2017; Plenge et al., 
2005). We found in our GRAS database, that two SNPs: rs3087243 (A/G) and 
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rs11571316 (A/G) of the human CTLA4 gene were associated with NMDAR1-AB 
IgA+IgG seropositivity. However, in our mouse study with CTLA4-AB treatment 
for 4 weeks, we did not find an increase of NMDAR1-AB in the CTLA4-AB treated 
group compared to the control IgG treated group 5 weeks after the last treatment. 
These negative results triggered our next hypothesis: there might be immune 
challenges required in addition to CTLA4-AB treatment.  
(IV) Chronic stress mouse model. According to our previous report that 
there is a high seroprevalence of NMDAR1-AB (especially the IgA class) in young 
migrants and monkeys (baboons and rhesus macaques), and we hypothesized 
that chronic life stress might contribute to the NMDAR1-AB production in those 
young individuals (Pan et al., 2019). To prove it, we designed a chronic life stress 
model in mice by housing the mice in rat environment, while the control mice 
stayed in the standard mouse environment. Here, we observed higher NMDAR1-
AB seroprevalence, especially IgA carriers, in WT mice housed in rat environment 
compared to mouse environment. Besides, mice (NMDAR1-AB negative) housed 
in rat environment also showed a depressive phenotype in tail suspension test. 
ApoE-/- mice (compromised BBB) who carried the NMDAR1-AB showed anti-
depressant behavior compared to WT NMDAR1-AB carriers by tail suspension 
test. Moreover, human ApoE4+NMDAR1-AB carriers have lower depressive and 
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Personal contribution: I was responsible for the conduction of most of the 
experiments, and data analyses under the supervison of HE and FL: blood 
collection from all mice; NMDAR1-AB determination in old WT and ApoE-/- mice 
(Figure 1a,b,c,d), human stroke patients (Figure 1e,f), human migrants (Figure 
3f), CTLA4-AB/control IgG treated mice (Figure 2h), chronic stress mice (Figure  
3c,d,e); data organization and analysis of cryolesion mice seropositivity (Figure 
2b,c); CTLA4-AB confirmation by flow cytometry (Figure 2f, under the guidance 
of FL) and spleen cytospin (Figure 2g); cFos experiment and quantification 
(Figure 3a); illustration images generation (Figure 2g, Figure 3a right panel); flow 
cytometry of blood, lung and small intestine of the chronic stress young cohort 
(data not shown); behavioral tests in the chonic stress young cohort (Figure 3g). 
After all the data analyses, I prepared the figures under the guidance of HE, and 
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Summary and outlook 
From the previous work of our group in this field, we found comparable 
seroprevalence of NMDAR1-AB in human across healthy and disease groups, 
increasing with age. The NMDAR1-AB in those individuals are also functional 
confirmed by internalization test, electrophysiology test, and they share similar 
epitopes among different Ig classes (IgA, IgG and IgM) (Castillo-Gomez et al., 
2017; Dahm et al., 2014; Ehrenreich, 2017, 2018; Hammer et al., 2014).  
In the 1st project, we explored the seroprevalence in non-human mammals, and 
studied the effects of NMDAR1-AB in mice by an immunization model. 
(I) The seroprevalence of NMDAR1-AB in non-human mammals. We 
detected the NMDAR1-AB in dogs, cats, mice, rats in an age-dependent pattern. 
The NMDAR1-AB in baboons and rhesus macaques are exceptional, as they 
already had a high seroprevalence at an early age. Thus, we hypothesized that 
chronic life stress maybe related to the NMDAR1-AB production. Driven by this 
hypothesis, we tested human migrants who also had chronic life stress and found 
a high seroprevalence of NMDAR1-AB (prominent IgA class) at an early age too.  
(II) We used an active immunization mouse model to study the effect 
of carrying NMDAR1-AB. We immunized both ApoE-/- and WT mice with 
GluN1 antigen cocktail containing 4 different peptides against NMDA receptor 
extracellular structure. We confirmed the high titer of NMDAR1-AB IgG class by 
ELISA, and the kinetics of NMDAR1-AB production is similar to ovalbumin. In 
addition, the ApoE-/- mice who also carried the NMDAR1-AB showed higher 
locomotion in open field after MK801 challenge compared to the WT mice AB 
carriers. This result confirmed the functionality of the endogenously produced 
NMDAR1-AB in terms of hypofunction hypothesis of NMDA receptors (Hammer 
et al., 2014; Vishnoi et al., 2015). However, the mice did not develop anti-
NMDAR encephalitis although there were high titers of NMDAR1-AB IgG class 
produced endogenously, which is contradictory to the findings of Dalmau 
(Dalmau et al., 2008; Dalmau et al., 2018; Dalmau et al., 2011; Dalmau et al., 
2007). In our mouse model, circulating NMDAR1-AB (IgG class) in healthy mice 
does not result in anti-NMDAR encephalitis.   
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Jones et al. published an immunization mouse model in July 2019 with NMDA 
receptor holoprotein, and they reported that the mice developed fulminant anti-
NMDAR encephalitis (Jones et al., 2019). Although we found the immunization 
strategy is elegant, there are still some questions remaining to be addressed in 
this study. For example, saline or empty liposome was used as controls which may 
not be adequate to control for the liposome-embedded native NMDA receptors. 
It would be interesting to add an additional liposome-embedded protein (e.g. 
GABA receptor) as controls (Ehrenreich et al., 2019). Our hypothesis remains 
that pre-existing encephalitis plus the circulating NMDAR1-AB will cause the 
typical Dalmau anti-NMDAR encephalitis model. The project aiming to prove the 
hypothesis is currently running in our group, we hope to uncover the mechanism 
behind the disease soon. 
The 2nd project aimed to find the potential inducers of the NMDAR1-AB.  
(I) We observed the spontaneous NMDAR1-AB course in a 
longitudinal study both in mice and humans. We found the fluctuation of 
the NMDAR1-AB in both ApoE-/- and WT mice, which means that we saw one can 
gain or lose the AB, or stay positive or negative over a 3-6 months’ time period. 
The same phenomenon was seen in human ischemic stroke patients from 24h of 
the symptom onset till 1-3 years after stroke. These findings indicated that 
NMDAR1-AB belong to the normal autoantibody repertoire, and the specific B 
cell clone can be stimulated under certain circumstances, e.g. infection or trauma, 
etc. Similar fluctuation of autoantibodies were seen in other studies, for instance 
for type 1 diabetes (Endesfelder et al., 2019); or SLE (Arbuckle et al., 2003).  
In type 1 diabetes, Endesfelder et al performed a longitudinal study in children 
who were at risk genetically for developing type 1 diabetes, which was published 
in 2019. The authors reported the children were stable-positive for insulin 
autoantibodies (IAA) and insulinoma-associated antigen 2 autoantibodies (IA-
2A) on follow up had the highest risk of diabetes compared to those who were 
transitionally positive or negative (Endesfelder et al., 2019). In SLE, 
autoantibodies including antinuclear antibodies (ANAs), anti–double-stranded 
DNA antibodies, etc. are typically present many years before the diagnosis 
(Arbuckle et al., 2003). It’s also common to find ANA positivity in the general 
population, also supporting the fact that autoantibodies are part of a healthy 
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immune response supported together with our findings (Castillo-Gomez et al., 
2017; Dahm et al., 2014; Hammer et al., 2014; Pan et al., 2019). Thus detecting 
of autoantibodies is not sufficient to predict diseases, it remains a challenge to 
uncover the mechanism of the transition from health to disease (Olsen et al., 
2014).   
(II) We conducted cryolesion surgery (brain injury model) in mice as 
a potential inducer, and a higher diversity of NMDAR1-AB in the lesion mice 
was observed compared to the sham mice. The cryolesion mice also had more IgG 
and IgM classes compared to the sham mice, however, the IgA class stays 
comparable between the two groups. This is an interesting finding, as we 
observed that brain lesion had an effect on the young mice, but not in the stroke 
patients (relatively old) who also had a lesion in the brain. This could probably be 
explained by the efficacy of the immune system at young and old age (Linton et 
al., 2004; Nikolich-Zugich, 2018).  
(III) We tried the immune check point inhibitor CTLA4-AB as a 
potential inducer, as we found CTLA4 SNPs (rs3087243 and rs11571316) 
were associated with NMDAR1-AB in human. However, in our experimental 
setup, no increase of NMDAR1-AB in mice treated with CTLA4-AB was observed 
compared to the control IgG treated mice.  
CTLA4 is cytotoxic T lymphocyte associated protein 4, exclusively expressed on T 
lymphocytes, constitutively by Treg cells and transiently on activated T cells. It 
works as a co-inhibitory signal, and it is an essential immune checkpoint to 
maintain self-tolerance and protecting the host form tissue damage (Murphy, 
2012). Checkpoint inhibitors are used for treating cancers, and the findings were 
awarded for Nobel Prize in 2018. The antibody against CTLA4 (ipilimumab) was 
approved for treating metastatic melanoma by the Food and Drug Administration 
(FDA) in 2011. The treatment mechanism is by blocking CTLA4 (competing with 
CD28 to bind with B7 ligand), CD28 on the T cell surface could to bind with B7 
ligand on the antigen presenting cells (APCs), thus T cells can be activated, and 
migrate to the cancer tissue, resulting in attacking cancer cells (Abril-Rodriguez 
et al., 2017). There were studies showed that melanoma patients after treatment 
with ipilimumab often developed autoantibodies (Bartels et al., 2019), and many 
autoimmune diseases such as colitis, dermatitis, hepatitis etc. (de Moel et al., 
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2019; June et al., 2017). There were also studies reporting that the CTLA4 
expression increase with aging in both humans and mice (Channappanavar et al., 
2009; Leng et al., 2002), and we reported that the NMDAR1-AB increase with 
aging in both human and animals (Castillo-Gomez et al., 2017; Dahm et al., 2014; 
Hammer et al., 2014; Pan et al., 2019). We still cannot exclude the probability 
that CTLA4-AB being an inducer of NMDAR1-AB formation. Therefore, we 
updated our hypothesis: to stimulate NMDAR1-AB production by the treatment 
of CTLA4-AB, additional immune challenges need to be considered. The project 
driven by this hypothesis is also running in our group currently.  
(IV) We used a chronic stress mouse model to prove our hypothesis 
from project 1: Chronic life stress may relates to NMDAR1-AB 
production. We designed a mouse model that allowed us to apply chronic stress 
in mice without interfering in their daily lives. The mice were transferred to the 
rat (predator of mice) environment. They did not have direct contact with rats, 
but they had direct access to the same environment air. We observed an increase 
of NMDAR1-AB especially IgA class in the WT mice housed in the rat 
environment compared to the mice housed in the mouse environment as controls. 
However, we did not observe NMDAR1-AB changes in ApoE-/- mice. The 
possible explanation is that the NMDAR1-AB could reach the brain through the 
compromised BBB and bind to the NMDA receptors, thus there was no difference 
in the periphery (Castillo-Gomez E, 2016; Zerche et al., 2015). Meanwhile, the 
mice in the rat environment showed depression signs as compared to the controls 
in the tail suspension test. Moreover, the ApoE-/- mice who had a compromised 
BBB and also carried the NMDAR1-AB showed less depressive phenotype 
compared the WT mice who carried NMDAR1-AB. In our human study, we 
observed that individuals who had a compromised BBB (APOE4+) and were 
NDMAR1-AB carriers had less depression and anxiety score.  
We proved that the rat environment is stressful for the mice by cFos 
quantification in the hippocampus and hypothalamus in the mouse brains. cFos 
is an immediate early gene, it was used as a stress marker as it reflects the activity 
of the cells (Canteras et al., 2008; Cullinan et al., 1995; Hoffman GE, 1993; 
Martinez et al., 2008). However, we did not have a good chronic stress marker, as 
it was a mild chronic stress paradigm over 30 weeks. The classical stress marker 
corticosterone is frequently used in acute stress paradigms (Sapolsky et al., 2000) 
                                                                                 SUMMARY AND OUTLOOK 
67 
or reported reflecting variation in metabolic rate independent of stress (Jimeno 
et al., 2018), we did not see any difference in a chronic period (data not shown). 
Besides, the blood sampling methods seem also to have an impact on the level of 
plasma corticosterone, the samples obtained from retro-orbital (our strategy) 
have a much higher level of corticosterone compared to other methods, e.g. via 
tail snip. (Kim, S. et al., 2018). However, we did not have other choices as we need 
sufficient amount of blood samples (minimizing invasion to the mice) for both 
flow cytometry and NMDAR1-AB determination in the plasma. We also tried with 
another marker: ghrelin. Ghrelin is a hormone produced in gastrointestinal tract, 
it regulated food intake and body weight, also controls glucose metabolism 
(Sakata et al., 2010; Wiedmer et al., 2007). It was proposed to be related to stress 
response and used as a stress marker (Sominsky et al., 2017; Yousufzai et al., 
2018). However, we did not observe any difference between the mice house in the 
mouse and rat environment at the end of the study (data not shown). We also did 
not observe any difference regarding food intake and body weight (data not 
shown) between the mice in mouse and rat environment, which fits to the ghrelin 
results. The possible explanation could be that our stress paradigm is too mild to 
induce the endocrine hormone changes, or the mice slowly adapt to the rat 
environment so that we could not detect the differences at these time points. As 
we observed the depressive behavior in the mice in the rat environment by tail 
suspension test, we believe the paradigm is valid enough to study the impact of 
chronic stress on NMDAR1-AB formation. Indeed, we observed there was an 
increased NMDAR1-AB seropositivity in the mice housed in the rat environment, 
especially IgA class, which fits to our hypothesis. Compared to the results from 
the cryolesion mice where we observed IgG+IgM increase instead of IgA; it 
became very interesting. So far, there were no studies reporting the Ig class 
specificity by the inducers, and the mechanism behind needs to be pursed further.  
As IgA is secreted by the mucosal membrane, we wondered whether there is a 
difference regarding the immune system in the lung and small intestine. 
However, we did not observe considerable changes in the major immune cells 
composition neither between the two environments, nor seropositive and 
seronegative mice in flow cytometry analysis in blood, lung and small intestine.  
These results suggested that there is no inflammation in the periphery in the mice 
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from the chronic stress study. In addition, we are still analyzing the inflammation 
markers in the brain in the mice from the chronic stress study.  
Besides discussed above, there are still a lot of questions which need to be 
addressed in the future work. For example, under which circumstances, the 
specific B/T cell clone will be activated? As B1 cells were thought to be associated 
with autoimmune disease (Linton et al., 2004), are they also involved in the 
NMDAR1-AB production? Some of the questions are integrated in current 
running projects in our group. We hope to uncover the mechanism of the anti-
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List of abbreviations 
 
AIRE Autoimmune regulator 
ANAs Antinuclear antibodies 
APCs Antigen presenting cells 
ApoE Apolipoprotein E 
APS-1 Autoimmune polyendocrine syndrome type 1 
BBB Blood-brain barrier 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CTLA4 Cytotoxic T-lymphocyte-associated antigen 4 
CypA Cyclophilin A 
ELISA Enzyme-Linked Immunosorbent Assay 
EPSP Excitatory postsynaptic potential 
FACS Fluorescence-activated cell sorting 
IA-2A Insulinoma-associated antigen 2 autoantibodies 
IAA Insulin autoantibodies 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
iGluR Ionotropic glutamate receptor 
IL17 Interleukin 17 
LTP Long-term potentiation 
mGluR Metabotropic glutamate receptor 
MK801 Dizocilpine 
NMDA receptor N-methyl-D-aspartate receptor 
NMDAR1-AB Antibodies against NMDA receptor subunit GluN1 (NR1) 
SLE Systemic lupus erythematosus 
SNP Single-nucleotide polymorphism 
Th cells T helper cells 
TLR Toll-like Receptor 
TNF-α Tumor necrosis factor alpha 
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